S Kimoto, K Muraki, M Toritsuka, S Mugikura, K Kajiwara, T Kishimoto, E Illingworth, K Tanigaki
Index: Transl. Psychiatry 2 , e146, (2012)
Full Text: HTML
The 22q11.2 microdeletion is one of the highest genetic risk factors for schizophrenia. It is not well understood which interactions of deleted genes in 22q11.2 regions are responsible for the pathogenesis of schizophrenia, but catechol-O-methytransferase (COMT) is among the candidates. Df1/+ mice are 22q11.2 deletion syndrome (22q11DS) model mice with a hemizygous deletion of 18 genes in the 22q11-related region. Df1/+ mice showed enhanced response to the dopamine D1 agonist, SKF38393, and the N-methyl-D-aspartate antagonist, MK801, which can be normalized by a GABA(A) receptor agonist, bretazenil, or a GABA(A) α2/α3 receptor agonist, SL651498. Here, we demonstrated the curing effects of virus-mediated reintroduction of Comt to the prefrontal cortex (PFC) in Df1/+ mice. In contrast, both Comt overexpression and Comt inhibition caused an abnormal responsiveness to Bretazenil, a GABA(A) receptor agonist in control mice. Comt overexpression increased MK801-induced interneuronal activation and GABA release in the PFC. The expression levels of GABA-related genes such as Gabrb2 (GABA(A)receptor β2), Gad2 (glutamic acid decarboxylase 65 (Gad65)) and Reln (Reelin) correlate with a Comt expression level in PFC. Our data suggest that Comt-mediated regulation of GABAergic system might be involved in the behavioral pathogenesis of Df1/+ mice.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Bretazenil
CAS:84379-13-5 |
C19H20BrN3O3 |
A Comparison of the α2/3/5 Selective Positive Allosteric Mod...
2011-01-01 [Adv. Pharmacol. Sci. 2011 , 608912, (2011)] |
A comparison of chlordiazepoxide, bretazenil, L838,417 and z...
2005-11-01 [Psychopharmacology 182(4) , 475-84, (2005)] |
Contextual fear conditioning and baseline startle responses ...
2000-09-01 [Behav. Pharmacol. 11(6) , 495-504, (2000)] |
Self-administration of bretazenil under progressive-ratio sc...
2011-01-15 [Drug Alcohol Depend. 113(2-3) , 157-64, (2011)] |
Differential behavioral effects of low efficacy positive GAB...
2006-02-01 [Br. J. Pharmacol. 147(3) , 260-8, (2006)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved